Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 865-870

  Tapaninen, Tuija ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

ABCB1 haplotypes; Aliskiren; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ALISKIREN; MULTIDRUG RESISTANCE PROTEIN 1; RENIN INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; FEMALE; FUMARATES; HAPLOTYPES; HUMANS; MALE; P-GLYCOPROTEIN; RENIN;

EID: 77956185912     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0836-z     Document Type: Article

References (31)

1. F Waldmeier U Glaenzel B Wirz L Oberer D Schmid M Seiberling J Valencia GJ Riviere P End S Vaidyanathan 2007 Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers Drug Metab Dispos 35 8 1418 1428 10.1124/dmd.106.013797 1:CAS:528: DC%2BD2sXosVKqurg%3D 17510248
2. S Vaidyanathan G Camenisch H Schuetz C Reynolds CM Yeh MN Bizot HA Dieterich D Howard WP Dole 2008 Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren J Clin Pharmacol 48 11 1323 1338 10.1177/0091270008323258 1:CAS:528: DC%2BD1cXhtlyrs7bK 18784280
3. MF Fromm 2004 Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol Sci 25 8 423 429 10.1016/j.tips.2004.06.002 1:CAS:528:DC%2BD2cXmtVaht7Y%3D 15276711
4. KM Giacomini SM Huang DJ Tweedie LZ Benet KL Brouwer X Chu A Dahlin R Evers V Fischer KM Hillgren KA Hoffmaster T Ishikawa D Keppler RB Kim CA Lee M Niemi JW Polli Y Sugiyama PW Swaan JA Ware SH Wright S Wah Yee MJ Zamek-Gliszczynski L Zhang 2010 Membrane transporters in drug development Nat Rev Drug Discov 9 3 215 236 10.1038/nrd3028 1:CAS:528:DC%2BC3cXisFelu74%3D 20190787
5. KT Olkkola JT Backman PJ Neuvonen 1994 Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 55 5 481 485 1:STN:280:DyaK2c3js1ynsA%3D%3D 8181191
6. KM Jalava J Partanen PJ Neuvonen 1997 Itraconazole decreases renal clearance of digoxin Ther Drug Monit 19 6 609 613 10.1097/00007691-199712000- 00001 1:CAS:528:DyaK2sXotV2lsbg%3D 9421099
7. EJ Wang K Lew CN Casciano RP Clement WW Johnson 2002 Interaction of common azole antifungals with P glycoprotein Antimicrob Agents Chemother 46 1 160 165 10.1128/AAC.46.1.160-165.2002 1:CAS:528:DC%2BD38XjtVejtQ%3D%3D 11751127
8. US Rao GA Scarborough 1994 Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein Mol Pharmacol 45 4 773 776 1:CAS:528:DyaK2cXivV2lurg%3D 7514263
9. LI Kajosaari M Niemi M Neuvonen J Laitila PJ Neuvonen JT Backman 2005 Cyclosporine markedly raises the plasma concentrations of repaglinide Clin Pharmacol Ther 78 4 388 399 10.1016/j.clpt.2005.07.005 1:CAS:528: DC%2BD2MXhtVGrsb7J 16198658
10. T Tapaninen JT Backman KJ Kurkinen PJ Neuvonen M Niemi 2010 Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren J Clin Pharmacol 10.1177/0091270010365885 20400651
11. European Public Assessment Report for Rasilez. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm. Accessed 11 March 2010
12. B Greiner M Eichelbaum P Fritz HP Kreichgauer O von Richter J Zundler HK Kroemer 1999 The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J Clin Invest 104 2 147 153 10.1172/JCI6663 1:CAS:528: DyaK1MXkslSmsb8%3D 10411543
13. M Niemi JT Backman MF Fromm PJ Neuvonen KT Kivistö 2003 Pharmacokinetic interactions with rifampicin: clinical relevance Clin Pharmacokinet 42 9 819 850 10.2165/00003088-200342090-00003 1:CAS:528: DC%2BD3sXntl2htr8%3D 12882588
14. T Tapaninen PJ Neuvonen M Niemi 2010 Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren Eur J Clin Pharmacol 66 5 497 502 10.1007/s00228-010-0796-3 1:CAS:528:DC%2BC3cXksFKhsb8%3D 20179914
15. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmöller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 7 3473 3478 10.1073/pnas.050585397 1:CAS:528:DC%2BD3cXitlWqtL8%3D 10716719
16. C Kimchi-Sarfaty JM Oh IW Kim ZE Sauna AM Calcagno SV Ambudkar MM Gottesman 2007 A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 315 5811 525 528 10.1126/science.1135308 1:CAS:528:DC%2BD2sXotFCitA%3D%3D 17185560
17. JE Keskitalo KJ Kurkinen PJ Neuvonen M Niemi 2008 ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin Clin Pharmacol Ther 84 4 457 461 10.1038/clpt.2008.25 1:CAS:528:DC%2BD1cXhtFeitbnN 19238649
18. D Wang AD Johnson AC Papp DL Kroetz W Sadée 2005 Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability Pharmacogenet Genomics 15 10 693 704 10.1097/01.fpc.0000178311.02878. 83 1:CAS:528:DC%2BD2MXpslahtb4%3D 16141795
19. RB Kim BF Leake EF Choo GK Dresser SV Kubba UI Schwarz A Taylor HG Xie J McKinsey S Zhou LB Lan JD Schuetz EG Schuetz GR Wilkinson 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2 189 199 10.1067/mcp.2001.117412 1:CAS:528:DC%2BD3MXmslygs7o%3D 11503014
20. DL Kroetz C Pauli-Magnus LM Hodges CC Huang M Kawamoto SJ Johns D Stryke TE Ferrin J DeYoung T Taylor EJ Carlson I Herskowitz KM Giacomini AG Clark 2003 Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene Pharmacogenetics 13 8 481 494 10.1097/00008571- 200308000-00006 1:CAS:528:DC%2BD3sXlvV2jt7Y%3D 12893986
21. I Cascorbi T Gerloff A Johne C Meisel S Hoffmeyer M Schwab E Schaeffeler M Eichelbaum U Brinkmann I Roots 2001 Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 3 169 174 10.1067/mcp.2001.114164 1:CAS:528: DC%2BD3MXislylsb0%3D 11240981
22. GD Leschziner T Andrew M Pirmohamed MR Johnson 2007 ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research Pharmacogenomics J 7 3 154 179 10.1038/sj.tpj.6500413 1:CAS:528:DC%2BD2sXlsFOitbw%3D 16969364
23. K Kajinami ME Brousseau JM Ordovas EJ Schaefer 2004 Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am J Cardiol 93 8 1046 1050 10.1016/j.amjcard.2004.01.014 1:CAS:528:DC%2BD2cXjtVems7w%3D 15081455
24. M Fiegenbaum FR da Silveira CR Van der Sand LC Van der Sand ME Ferreira RC Pires MH Hutz 2005 The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment Clin Pharmacol Ther 78 5 551 558 10.1016/j.clpt.2005.08.003 1:CAS:528: DC%2BD2MXht1OltLfM 16321621
25. S Vaidyanathan V Jarugula HA Dieterich D Howard WP Dole 2008 Clinical pharmacokinetics and pharmacodynamics of aliskiren Clin Pharmacokinet 47 8 515 531 10.2165/00003088-200847080-00002 1:CAS:528:DC%2BD1cXhtVOgu7fK 18611061
26. KT Kivistö M Niemi E Schaeffeler K Pitkälä R Tilvis MF Fromm M Schwab M Eichelbaum T Strandberg 2004 Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics 14 8 523 525 10.1097/01.fpc.0000114762.78957.a5 15284534
27. V Jarugula CM Yeh D Howard C Bush DL Keefe WP Dole 2010 Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren J Clin Pharmacol 10.1177/0091270009359525
28. C Verstuyft M Schwab E Schaeffeler R Kerb U Brinkmann P Jaillon C Funck-Brentano L Becquemont 2003 Digoxin pharmacokinetics and MDR1 genetic polymorphisms Eur J Clin Pharmacol 58 12 809 812 1:CAS:528:DC%2BD3sXltFGgu7Y%3D 12698307
29. A Johne K Köpke T Gerloff I Mai S Rietbrock C Meisel S Hoffmeyer R Kerb MF Fromm U Brinkmann M Eichelbaum J Brockmöller I Cascorbi I Roots 2002 Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin Pharmacol Ther 72 5 584 594 10.1067/mcp.2002. 129196 1:CAS:528:DC%2BD38XpsFSisbg%3D 12426522
30. T Sakaeda T Nakamura M Horinouchi M Kakumoto N Ohmoto T Sakai Y Morita T Tamura N Aoyama M Hirai M Kasuga K Okumura 2001 MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects Pharm Res 18 10 1400 1404 10.1023/A:1012244520615 1:CAS:528: DC%2BD3MXotVShsL0%3D 11697464
31. B Chowbay H Li M David YB Cheung EJ Lee 2005 Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression Br J Clin Pharmacol 60 2 159 171 10.1111/j.1365-2125.2005.02392.x 1:CAS:528:DC%2BD2MXps1Kktbc%3D 16042669